×
About 44,600 results

ALLMedicine™ Cirrhosis Center

Research & Reviews  14,877 results

Long non‑coding RNA MBI‑52 inhibits the development of liver fibrosis by regulating the...
https://doi.org/10.3892/mmr.2021.12549
Molecular Medicine Reports; Li Y, Liu P et. al.

Dec 2nd, 2021 - Liver fibrosis is a wound healing response triggered by liver injury. In severe cases, it may develop into liver cirrhosis, liver cancer and liver failure. Long non‑coding RNAs (lncRNAs) play key roles in the development of liver fibrosis. The pre...

Supporting clinician wellbeing and organizational resilience
https://www.mdedge.com/gihepnews/article/249202/mixed-topics/supporting-clinician-wellbeing-and-organizational-resilience

Dec 1st, 2021 - The COVID-19 pandemic highlighted a major gap in our institutional infrastructure in medicine – specifically, the absence of established policies and programs to support clinician wellbeing and organizational resilience. Dr.

State of the art treatment of HBV hepatocellular carcinoma and the role of HBsAg post l...
https://doi.org/10.1111/liv.15124
Liver International : Official Journal of the Internation... Schemmer P, Burra P et. al.

Dec 1st, 2021 - Chronic hepatitis B virus (HBV) infection is the major aetiology of hepatocellular carcinoma (HCC). The optimal goal of therapy, hepatitis B surface antigen (HBsAg) loss and anti-HBs production, is achieved rarely and HBsAg-associated HCC risk is ...

Significant metabolic alterations in patients with hepatitis B virus replication observ...
https://doi.org/10.1080/1061186X.2021.2009841
Journal of Drug Targeting; Yu L, Zeng Z et. al.

Dec 1st, 2021 - Until now, the metabolic effects of hepatitis B virus (HBV) replication on the progression of hepatic diseases (hepatitis, cirrhosis, and liver cancer) and liver functions have remained unexplored. Thus, a total of 199 hepatic disease patients wit...

see more →

Guidelines  36 results

AGA Clinical Practice Guideline on the Management of Coagulation Disorders in Patients ...
https://doi.org/10.1053/j.gastro.2021.08.015
Gastroenterology O'Shea RS, Davitkov P et. al.

Sep 29th, 2021 - AGA Clinical Practice Guideline on the Management of Coagulation Disorders in Patients With Cirrhosis.|2021|O'Shea RS,Davitkov P,Ko CW,Rajasekhar A,Su GL,|

AGA Technical Review on Coagulation in Cirrhosis.
https://doi.org/10.1053/j.gastro.2021.09.004
Gastroenterology Intagliata NM, Davitkov P et. al.

Sep 29th, 2021 - AGA Technical Review on Coagulation in Cirrhosis.|2021|Intagliata NM,Davitkov P,Allen AM,Falck-Ytter YT,Stine JG,|

NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF PORTAL HYPERTENSION.
https://doi.org/10.1016/j.clinre.2021.101767
Clinics and Research in Hepatology and Gastroenterology; Thabut D, Weil D et. al.

Aug 1st, 2021 - Compensated advanced chronic liver disease (cACLD) describes the spectrum of advanced fibrosis/cirrhosis in asymptomatic patients at risk of developing clinically significant portal hypertension (CSPH, defined by a hepatic venous pressure gradient...

Non-invasive diagnosis and follow-up of primary biliary cholangitis.
https://doi.org/10.1016/j.clinre.2021.101770
Clinics and Research in Hepatology and Gastroenterology; Corpechot C, Heurgue A et. al.

Aug 1st, 2021 - Primary biliary cholangitis (PBC) is a chronic inflammatory disease of the intra-hepatic bile ducts [1]. It is characterised biologically by chronic cholestasis associated with the presence of specific autoantibodies, and histologically by lesions...

Non-invasive diagnosis and follow-up of primary sclerosing cholangitis.
https://doi.org/10.1016/j.clinre.2021.101775
Clinics and Research in Hepatology and Gastroenterology; Chazouillères O, Potier P et. al.

Aug 1st, 2021 - Primary sclerosing cholangitis (PSC) is a rare and chronic cholestatic liver disease of unknown cause commonly associated with inflammatory bowel disease (IBD) and characterized by progressive obliterative fibro-inflammation of the biliary tree. A...

see more →

Drugs  582 results see all →

Clinicaltrials.gov  769 results

Non-Pharmaceutical Intervention for Cirrhotic Cramps Reduction: The NICCles Trial
https://clinicaltrials.gov/ct2/show/NCT04650295

Nov 25th, 2021 - This clinical trial is evaluating the feasibility of using a non-pharmaceutical treatment to improve the symptoms and severity of muscle cramps in patients with cirrhosis. Eligible participants will be randomized to the treatment arm or control gr...

Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease
https://clinicaltrials.gov/ct2/show/NCT02217345

Nov 25th, 2021 - Nonalcoholic fatty liver disease (NAFLD), fatty infiltration of the liver in the absence of alcohol use, is an increasingly recognized complication of obesity, with prevalence estimates of about 30% of individuals in the United States. A subset of...

Clinical Application of Fibroblast Activation Protein PET/MRI in Liver Fibrosis
https://clinicaltrials.gov/ct2/show/NCT04605939

Nov 24th, 2021 - Liver fibrosis is a key step in the development of various chronic liver diseases (viral hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease, autoimmune liver disease, etc.) to cirrhosis and an important link that affects the pro...

SMS-based Lifestyle Intervention for Patients With Liver Cirrhosis With Previous Hepathic Encephalopathy
https://clinicaltrials.gov/ct2/show/NCT02811887

Nov 19th, 2021 - Physical exercise and other interventions focused on lifestyle factors have not only the potential to increase physical functioning and capacity, but also to affect fundamental aspects of disease, increase quality of life, and may even increase su...

Evaluation of Patients With Liver Disease
https://clinicaltrials.gov/ct2/show/NCT00001971

Nov 18th, 2021 - This is a general clinical research protocol to allow for evaluation, investigation and long-term follow up of patients who have an acute or chronic liver disease. The protocol is designed to study the natural history and pathogenesis of various l...

see more →

News  1,531 results

Supporting clinician wellbeing and organizational resilience
https://www.mdedge.com/gihepnews/article/249202/mixed-topics/supporting-clinician-wellbeing-and-organizational-resilience

Dec 1st, 2021 - The COVID-19 pandemic highlighted a major gap in our institutional infrastructure in medicine – specifically, the absence of established policies and programs to support clinician wellbeing and organizational resilience. Dr.

Liver Cancer Risk Lingers Even After HCV Eradication
https://www.medscape.com/viewarticle/963101

Nov 17th, 2021 - Although the risk for liver cancer diminishes for patients with hepatitis C virus (HCV) infections for whom virus is eliminated with direct-acting antiviral (DAA) drugs, these patients are not out of the woods, and those who do not have a sustaine...

Age, Geography Predict COVID-19 Vaccination of Vets With Cirrhosis
https://www.medscape.com/viewarticle/963021

Nov 16th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Vaccination against SARS-CoV-2 infection can protect patients with liver cirrhosis from decompensation, hospitalization, and death, but getting th...

AGA Clinical Care Pathway: Screening, diagnosis, and treatment of NAFLD and NASH
https://www.mdedge.com/internalmedicine/article/248632/gastroenterology/aga-clinical-care-pathway-screening-diagnosis-and
Will Pass

Nov 12th, 2021 - The American Gastroenterological Association recently published a Clinical Care Pathway for screening, diagnosis, and treatment of patients with nonalcoholic fatty liver disease (NAFLD). Recommendations are intended for a spectrum of clinical sett.

Alcohol-Related Liver Disease Severity Increased During COVID-19
https://www.medscape.com/viewarticle/962789

Nov 11th, 2021 - Over the course of the COVID-19 pandemic, alcohol-related liver disease has increased in severity, a finding that is likely related to higher consumption of alcohol and reduced care. The difference was notable in higher Model for End-Stage Liver D...

see more →

Patient Education  45 results see all →